Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To evaluate incidence of adverse events. After: Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects.
Planned enrollment increased by 25 participants
Before: 12 participants (planned). After: 37 participants (planned).
Phase changed
Before: PHASE1, PHASE2. After: PHASE2, PHASE3.